Drug Patents owned by Tg Theraps

1. Drug name - UKONIQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9150579 TG THERAPS Selective PI3K delta inhibitors
Jul, 2033

(10 years from now)

US10570142 TG THERAPS Selective PI3K delta inhibitors
Jul, 2033

(10 years from now)

US9969740 TG THERAPS Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations
May, 2035

(12 years from now)

US10414773 TG THERAPS Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations
May, 2035

(12 years from now)

CN104470923A TG THERAPS Selective Pi3K Inhibitor
Jul, 2033

(10 years from now)

CN104470923B TG THERAPS Selective Pi3K Inhibitor
Jul, 2033

(10 years from now)

CN106661030B TG THERAPS Improved Form For Pharmaceutical Preparation Of Pi3K Inhibitors
May, 2035

(12 years from now)

CN106661030A TG THERAPS Improved Form For Pi3K Selective Inhibitor In The Pharmaceutical Formulation
May, 2035

(12 years from now)

IN201500204P4 TG THERAPS Selective Pi3K Delta Inhibitors
Jul, 2033

(10 years from now)

IN358166B TG THERAPS Selective Pi3K Delta Inhibitors
Jul, 2033

(10 years from now)

IN201647042988A TG THERAPS Improved Forms Of A Pi3K Delta Selective Inhibitor For Use In Pharmaceutical Formulations
May, 2035

(12 years from now)

IN328766B TG THERAPS Improved Forms Of A Pi3K Delta Selective Inhibitor For Use In Pharmaceutical Formulations
May, 2035

(12 years from now)

EP2870157B1 TG THERAPS Selective Pi3K Delta Inhibitors
Jul, 2033

(10 years from now)

EP3260455B1 TG THERAPS Selective Pi3K Delta Inhibitors
Jul, 2033

(10 years from now)

EP2870157A1 TG THERAPS Selective Pi3K Delta Inhibitors
Jul, 2033

(10 years from now)

EP3260455A1 TG THERAPS Selective Pi3K Delta Inhibitors
Jul, 2033

(10 years from now)

EP3149000B1 TG THERAPS Crystalline Tosylate Salt Of A Pi3K Delta Selective Inhibitor For Use In Pharmaceutical Formulations
May, 2035

(12 years from now)

EP3149000A1 TG THERAPS Crystalline Tosylate Salt Of A Pi3K Delta Selective Inhibitor For Use In Pharmaceutical Formulations
May, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9669033 TG THERAPS Selective PI3K delta inhibitors Jul, 2033

(10 years from now)

US10981919 TG THERAPS Selective PI3K delta inhibitors Jul, 2033

(10 years from now)

US10072013 TG THERAPS Selective PI3K delta inhibitors Jul, 2033

(10 years from now)

US10947244 TG THERAPS Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations May, 2035

(12 years from now)

Drugs and Companies using UMBRALISIB TOSYLATE ingredient

Treatment: Relapsed or refractory marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based regimen; relapsed or refractory follicular lymphoma (fl) who have received at least three prior lines of systemic therapy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.